DynamiCure

DynamiCure is adopting a platform-agnostic approach to discover and develop treatments aimed at addressing significant unmet medical needs in oncology and autoimmune diseases. Driven by science and passionate about advancing patient care, DynamiCure translates groundbreaking new insights on immune normalization into an innovative pipeline of candidates with first-in-class potential. Since its establishment in 2019, DynamiCure has identified and secured exclusive global rights to several novel targets and is rapidly advancing into clinical trials with monoclonal and bispecific therapeutic antibody candidates.